Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Contraception and dyslipidemia

R H Knopp1, J C LaRosa, R T Burkman

  • 1Northwest Lipid Research Clinic, University of Washington School of Medicine.

American Journal of Obstetrics and Gynecology
|June 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Relationship of self-effecacy to cholesterol lowering and dietary change in hyperlipidemia.

Annals of behavioral medicine : a publication of the Society of Behavioral Medicine·2013
Same author

The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials.

BMJ (Clinical research ed.)·2009
Same author

Effect of cholesterol-lowering diets on indices of depression and hostility.

Annals of behavioral medicine : a publication of the Society of Behavioral Medicine·2008
Same author

Plasma pancreatic polypeptide levels are associated with differences in body fat distribution in human subjects.

Diabetologia·2006
Same author

Coronary heart disease prevention in women: focus on lipids.

Minerva cardioangiologica·2006
Same author

Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans.

Diabetologia·2005

Cardiovascular disease risks from dyslipidemia vary by sex, with triglyceride/high-density lipoprotein ratios posing greater risks for middle-aged women. Oral contraceptives are generally safe for women with controlled cholesterol, but alternatives are advised for severe cases.

Area of Science:

  • Cardiology
  • Endocrinology
  • Women's Health

Background:

  • Cardiovascular disease (CVD) risks associated with dyslipidemia exhibit sex-specific differences.
  • While women have a lower incidence of heart disease due to longer lifespans, lifetime risk is equal to men, with increased incidence after age 65.
  • Major coronary events are infrequent in reproductive-age women using oral contraceptives (OCs), unless combined with risk factors like smoking, diabetes, or hypertension.

Purpose of the Study:

  • To analyze the differential risks of dyslipidemia-associated cardiovascular disease in women versus men.
  • To evaluate the safety of oral contraceptives (OCs) in women with varying lipid profiles and cardiovascular risk factors.
  • To provide guidance on contraceptive selection for hyperlipidemic women.

Main Methods:

Keywords:
Age FactorsAmericasBiologyCardiovascular Effects--womenContraceptionContraceptive MethodsContraceptive Usage--womenDemographic FactorsDeveloped CountriesFamily PlanningHealthLipid Metabolic Effects--womenLipidsNorth AmericaNorthern AmericaNutrition--womenOral ContraceptivesPhysiologyPopulationPopulation CharacteristicsRisk FactorsUnited States

Related Experiment Videos

  • Review of existing literature on dyslipidemia, cardiovascular disease, and oral contraceptive use in women.
  • Analysis of risk factors, including age, smoking, diabetes, hypertension, obesity, and lipid profiles (triglycerides, HDL, cholesterol).
  • Assessment of the impact of estrogen-progestin dose in OCs on cardiovascular risk.

Main Results:

  • The triglyceride/high-density lipoprotein ratio is a stronger CVD risk indicator in middle-aged women than in men.
  • Low-dose estrogen-progestin OCs do not appear to promote CVD and can be used by women with controlled cholesterol elevations.
  • High-dose estrogen OCs may increase thrombotic risk in women with severe hypercholesterolemia or high CVD risk, potentially accelerating coronary thrombosis.

Conclusions:

  • Contraceptive selection in hyperlipidemic women requires balancing CVD risks against pregnancy risks.
  • Women with severe, uncontrolled hypercholesterolemia or high CVD risk warrant alternative contraceptive methods.
  • Management of hypercholesterolemia should adhere to National Cholesterol Education Program guidelines, emphasizing lifestyle modifications.